[PBE] PowerShares Dynamic Biotech &Genome

Overview

Type of security: Fund

Tags: Active-Index, Biotech, Country, Equity, ETF, Health, Health care, Not Inversed, Stocks, U.S., Unleveraged

The data is delayed by 15 minutes.

 

Price: 40.48 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart PBE

Refresh chart

Strongest Trends Summary For PBE

PBE is in the long-term up 31% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

See how to gain 20% in 14 sec with TrendsInvesting

Technical Data
High 52 week60.27 Low 52 week43.44 Last close51.76 Last change-0.46%
RSI29.89 Average true range1.04 Beta0.95 Volume
Simple moving average 20 days-5.15% Simple moving average 50 days-4.39% Simple moving average 200 days-4.59%
Performance Data
Performance Week-5.67% Performance Month-6.95% Performance Quart-1.47% Performance Half-6.79%
Performance Year4.08% Performance Year-to-date9.96% Volatility daily1.58% Volatility weekly3.53%
Volatility monthly7.24% Volatility yearly25.07% Relative Volume0% Average Volume17.16 K
New High New Low
Funds Characteristics
30-day SEC yield-0.18 Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio Index dividend yield Median market cap Number of holdings30
Price to Book Value 6.56 Price to Earnings48.09 Total expense ratio0.63% Total net assets
Weighted market capitalization19.9 B

Info

Characteristics:
NAME VALUE
Total Expense Ratio0,63
30 Day Sec Yield-0,18
Number Of Holdings30
P/Bv Ratio6,56
P/E Ratio48,09
Weighted Market Capitalization19901
Top Holdings:
NAME VALUE
Amgen5,37
Sigma-aldrich5,34
Regeneron Pharmaceuticals4,88
Biogen Idec4,85
Illumina4,68
Alexion Pharmaceuticals4,65
Gilead Sciences4,62
Pharmacyclis3,9
Neogen3,06
Acorda Therapeutics3,05
Emergent Biosolutions3,01
Fei2,96
Bruker2,95
Sangamo Biosciences2,93
Luminex2,89
Waters2,87
Pdl Biopharma2,86
Arena Pharmaceuticals2,85
Techne2,83
Nektar Therapeutics2,78
Myriad Genetics2,78
Fluidigm2,77
Dyax2,73
United Therapeutics2,73
Insys Therapeutics2,72
Cubist Pharmaceuticals2,71
Immunogen2,68
Medivation2,64
Isis Pharmaceuticals2,49
Theravance2,46
Subindustries Breakdown:
NAME VALUE
Biotechnology66,89
Life Sciences Tools Services18,98
Specialty Chemicals5,34
Health Care Supplies3,06
Electronic Equipment Instruments2,96
Pharmaceuticals2,78
Company Size:
NAME VALUE
Large-cap Blend5,37
Large-cap Growth23,67
Mid-cap Blend7,8
Mid-cap Growth20,51
Mid-cap Value2,73
Small-cap Blend8,48
Small-cap Growth31,45

News

2019-09-06 15:07:07 | ETFs Poised to Benefit from Gene Editing Revolution

2019-09-04 15:18:07 | ETFs to Gain From the Booming Genomics Market

2019-08-29 07:39:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-08-27 10:05:02 | Amgen to Buy Celgene's Otezla: 5 ETF Drugs

2019-08-14 08:53:17 | 3 Charts That Suggest Now Is the Time to Buy Into Biotech

2019-08-07 06:45:10 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-08-05 12:00:04 | 7 Biotech ETFs That Should Remain Healthy

2019-07-16 07:01:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-06-21 09:15:01 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-06-18 09:55:01 | Pfizer-Array Biopharma Deal Bump Up Biotech ETFs

2019-05-30 06:53:10 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-05-10 13:00:05 | Top and Flop ETFs So Far in Q2

2019-05-08 08:03:12 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-04-12 07:23:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-04-10 16:44:08 | Global X Launches GNOM ETF to Tap Booming Genomics Space

2019-03-20 07:07:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-02-26 11:15:04 | Biotech ETFs Jump on Roche-Spark Deal

2019-02-25 13:59:35 | Spark Therapeutics Acquisition Sparks Rally in Biotechnology ETFs

2019-02-20 09:32:02 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-01-02 14:30:02 | A Financial Overview of Sangamo Therapeutics in December 2018

2018-12-13 07:32:12 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2018-11-21 09:47:02 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2018-11-20 14:03:48 | 7 Biotech ETFs to Consider for 2019

2018-10-30 08:08:12 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2018-10-25 14:05:02 | Amgen: Analysts’ Recommendations on October 25

2018-10-23 16:21:47 | Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth

2018-10-19 12:55:02 | Biogen: Revenue Growth Is Expected in Q3

2018-10-08 08:25:12 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2018-08-09 07:31:59 | What Analysts Recommend for Ionis after Q2 2018

2018-08-07 09:45:02 | Analysts Are Bullish on Sarepta Therapeutics

2018-08-06 09:40:08 | Analysts Have Mixed Opinions about Ionis

2018-07-31 15:52:29 | Biotech ETFs Rally as Illumina Tops Q2 Expectations

2018-05-24 16:13:59 | Ionis Pharmaceuticals’ Valuation on May 23

2018-04-12 07:19:11 | Is PowerShares Dynamic Biotechnology & Genome Portfolio PBE a Hot ETF Right Now?

2018-03-27 07:32:29 | How Ionis’s Spinraza Performed in 4Q17

2018-01-10 16:10:02 | Exploring Ionis’s 3Q17 Quarterly Revenue Trend

2017-09-21 14:13:18 | Gene-Editing Could Modify and Cure Disease: CRISPR vs. TALENs

2017-09-21 11:56:18 | A Shot in the Arm for the UK Life Sciences Industry?

2017-09-12 09:06:57 | How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17?

2017-08-23 16:18:38 | What’s Ionis Pharmaceuticals’ Valuation?

2017-07-10 14:35:56 | What Drove Biogen Stock in 2Q17?

2017-06-14 15:04:42 | How Incyte’s Valuation Has Changed since 1Q17 Results

2017-06-09 16:47:17 | Changes in Ionis Pharmaceuticals’ Valuation after 1Q17

2017-05-05 17:16:00 | ETF Flopper: Biotech Bungle

2017-03-13 17:46:09 | Time to Buy Biotech ETF?

2017-03-13 17:46:09 | Time to Buy Biotech ETFs?

2017-03-02 14:00:07 | Trump???s Immigration Plans an Overhang on Biotech ETFs?

2017-03-02 14:00:07 | Trump's Immigration Plans an Overhang on Biotech ETFs?

2017-03-01 09:06:38 | A Look at Incyte’s Product Portfolio

2017-01-27 16:30:09 | What Lies Ahead for Biotech ETFs in Trump Era?